Cargando…

Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma

BACKGROUND: The advent of immune checkpoint therapy has been a tremendous advance in cancer treatment. However, the responses are still insufficient in patients with soft tissue sarcoma (STS). We aimed to identify rational combinations to increase the response to immune checkpoint therapy and improv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Que, Yi, Zhang, Xiao-Long, Liu, Ze-Xian, Zhao, Jing-Jing, Pan, Qiu-Zhong, Wen, Xi-Zhi, Xiao, Wei, Xu, Bu-Shu, Hong, Dong-Chun, Guo, Tian-Hui, Shen, Lu-Jun, Fan, Wei-Jun, Chen, Huo-Ying, Weng, De-Sheng, Xu, Hai-Rong, Zhou, Peng-Hui, Zhang, Yi-Zhuo, Niu, Xiao-Hui, Zhang, Xing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919591/ https://www.ncbi.nlm.nih.gov/pubmed/33637599 http://dx.doi.org/10.1136/jitc-2020-001696

Ejemplares similares

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Chidamide Suppresses the Growth of Cholangiocarcinoma by Inhibiting HDAC3 and Promoting FOXO1 Acetylation
por: Li, Yongpan, et al.
Publicado: (2022)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl-2 pathway
por: Zhang, Hongwei, et al.
Publicado: (2021)

Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway
por: Wang, Hao, et al.
Publicado: (2020)

HDAC inhibitor confers radiosensitivity to prostate stem-like cells
por: Frame, F M, et al.
Publicado: (2013)

Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
por: Guan, Xu-Wen, et al.
Publicado: (2020)

Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia
por: Gu, Siyu, et al.
Publicado: (2023)

Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide
por: Chang, J, et al.
Publicado: (2012)

Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade
por: Hong, Dong-Chun, et al.
Publicado: (2023)

HDAC6 is associated with the formation of aortic dissection in human
por: Guo, Xian, et al.
Publicado: (2019)

Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer
por: Wang, Yumeng, et al.
Publicado: (2022)

Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer
por: Sun, Fan, et al.
Publicado: (2020)

Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma
por: Huang, Renhong, et al.
Publicado: (2018)

Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
por: Zhou, Liye, et al.
Publicado: (2022)

T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma
por: Wang, Xiaobin, et al.
Publicado: (2023)

CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
por: Zhou, Quan, et al.
Publicado: (2020)

Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types
por: Green, S R, et al.
Publicado: (2010)

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
por: Wu, Si-Yu, et al.
Publicado: (2021)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
por: Abe, Shinya, et al.
Publicado: (2022)

The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma
por: Wang, Xing, et al.
Publicado: (2021)

Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade
por: Xu, Lijun, et al.
Publicado: (2022)

Involvement of Hdac3-mediated inhibition of microRNA cluster 17-92 in bronchopulmonary dysplasia development
por: Wang, Di, et al.
Publicado: (2020)

New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis
por: Luan, Yi, et al.
Publicado: (2022)

A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
por: Kaliszczak, M, et al.
Publicado: (2013)

Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation
por: Marquardt, Viktoria, et al.
Publicado: (2023)

Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer
por: Zhang, Yan, et al.
Publicado: (2021)

FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report
por: Roussot, Nicolas, et al.
Publicado: (2023)

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
por: Peng, Xiao-Xiao, et al.
Publicado: (2020)

Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs
por: Ridolfi, E, et al.
Publicado: (2008)

HDAC1 and HDAC2 Regulate Oligodendrocyte Differentiation By Disrupting β-Catenin-TCF Interaction
por: Ye, Feng, et al.
Publicado: (2009)

A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
por: Ramos, Louise, et al.
Publicado: (2023)

Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
por: Gao, Hannan, et al.
Publicado: (2020)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)

Increased transcription of TSPO, HDAC2, and HDAC6 in the amygdala of males with alcohol use disorder
por: De Carvalho, Luana Martins, et al.
Publicado: (2020)

The Role of HDACs and HDACi in Cartilage and Osteoarthritis
por: Zhang, He, et al.
Publicado: (2020)

BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma
por: Gusyatiner, Olga, et al.
Publicado: (2021)

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
por: Yang, Weixiong, et al.
Publicado: (2022)

Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice
por: Küçükköse, Emre, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c6eeoc0ch8k2ud64e63q1pbc9j